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Abstract
With the inevitable selection of resistance to antimalarial drugs in treated populations, there is a need for new medicines to
enter the clinic and new targets to progress through the drug discovery pipeline. In this study we set out to develop a
transgenic rodent model for testing inhibitors of the Plasmodium falciparum cyclic GMP-dependent kinase in vivo. A model
was needed that would allow us to investigate whether differences in amino acid sequence of this enzyme between species
influences in vivo efficacy. Here we report the successful development of a transgenic P. berghei line in which the cyclic
GMP-dependent protein kinase (PKG) was replaced by the P. falciparum orthologue. We demonstrate that the P. falciparum
orthologue was able to functionally complement the endogenous P. berghei pkg gene throughout blood stage
development and early sexual development. However, subsequent development in the mosquito was severely
compromised. We show that this is due to a defect in the female lineage of the transgenic by using genetic crosses
with both male and female deficient P. berghei lines. This defect could be due to expression of a female-specific target in the
mosquito stages of P. berghei that cannot be phosphorylated by the P. falciparum kinase. Using a previously reported anti-
coccidial inhibitor of the cyclic GMP-dependent protein kinase, we show no difference in in vivo efficacy between the
transgenic and control P. berghei lines. This in vivo model will be useful for screening future generations of cyclic GMP-
dependent protein kinase inhibitors and allowing us to overcome any species-specific differences in the enzyme primary
sequence that would influence in vivo efficacy in the rodent model. The approach will also be applicable to in vivo testing of
other antimalarial compounds where the target is known.
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Introduction
In 2012, malaria caused an estimated 627,000 deaths (with an
uncertainty range of 473,000 to 789,000), mostly among African
children (http://www.who.int). The malaria burden has fallen
dramatically in some countries in recent years, likely due to scaling
up of interventions such as vector control programmes and the use
of artemisinin combination therapy (ACT) as the first line of
treatment. However, it has been firmly established in parts of
Southeast Asia that ACT has developed a reduced efficacy in
many patients [1,2] likely heralding resistance to this drug which
would be a public health disaster in the absence of alternative
treatments. It is therefore imperative that the drug discovery
pipeline receives new candidates and delivers products to the
clinic.
One potential candidate that has received attention in recent
years is the Plasmodium falciparum cGMP-dependent protein kinase
(PfPKG). PKG has diverse roles across eukaryotes. In mammals
PKG is encoded by two distinct genes: prkg1 (encoding two
isoforms, PKGIa and PKGIb) and prkg2, both of which are
downstream effectors of nitric oxide-stimulated cGMP signalling
and also atrial natriuretic peptide-stimulated cGMP signalling.
The PKGI isoforms have major roles in smooth muscle relaxation
and platelet aggregation, whereas PKGII is involved in processes
such as intestinal secretion, circadian rhythm and endochondreal
bone growth [3]. All PKG enzymes comprise a C-terminal
catalytic domain and an N-terminal regulatory domain in a single
polypeptide. Mammalian PKGs have two cGMP-binding domains
in the regulatory domain, whereas the malarial PKG has three
functional cGMP-binding domains as well as a degenerate fourth
domain which is required for optimal enzyme activation [4,5].
Binding of cGMP, dramatically changes the conformation of the
enzyme [6] allowing substrate binding and transfer of the c-
phosphate of ATP to a serine/threonine residue of the bound
substrate.
The PKG enzyme from Eimeria tenella was the focus of an earlier
anti-coccidial drug discovery program [7]. Highly specific,
selective lead compounds were shown to also inhibit Plasmodium
PKG [8,9]. These compounds have proven to be excellent tools
for investigating the biological role of PKG and cGMP signalling
in malaria parasites especially when used in conjunction with
transgenic parasites expressing an inhibitor-resistant PKG. The
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selectivity of these classes of PKG inhibitors (a pyrrole, compound
1 and an imidazopyridine, compound 2) relies on a rare structural
feature of the apicomplexan PKG enzyme. It has a threonine
residue (with a relatively small side chain) occupying the so-called
‘gatekeeper’ position. The presence of threonine in this position
allows inhibitor access to a small hydrophobic pocket adjacent to
the ATP-binding site of the kinase [10,11]. The gatekeeper
position of most protein kinases of the AGC superfamily in
mammals is occupied by an amino acid with a relatively bulky
amino acid (e.g. methionine in human PKG isoforms) which
prevents access of the inhibitor to the hydrophobic pocket. These
properties have been exploited in a chemical genetic approach to
functional analysis of PKG in coccidian and malaria parasites.
Recombinant parasite PKGs in which the gatekeeper residue is
mutated from threonine to methionine or glutamine are dramat-
ically less sensitive to the inhibitors with IC50 values 3–4 logs
higher using in vitro kinase assays [9,10]. Transgenic parasites
expressing these mutant PKGs are inhibitor resistant. Testing of
wild type and transgenic gatekeeper mutant lines in parallel with
PKG inhibitors provides a means of providing direct evidence of a
role for PKG in a cellular process or differentiation stage of
interest. Using this approach we have previously demonstrated a
role for PfPKG in sexual development. PKG inhibitors block the
initial step of gametogenesis in wild type P. falciparum parasites,
whereas this process occurs normally in the inhibitor-treated
gatekeeper mutant parasites [9]. We have also established a role
for PfPKG in asexual blood stage schizont rupture and merozoite
egress [12]. Additional work has shown that at least part of the
underlying mechanism of PKG inhibition at this life cycle stage is a
complete block in the function of the protease PfSUB1 which is
essential for merozoite egress [13]. The proteolytic processing of
the MSP1 complex and SERA proteins by PfSUB1 is blocked by
PKG inhibitors. PKG inhibitors have no effect on the catalytic
activity of PfSUB1 or its trafficking to the exonemes; a discrete set
of apical organelles from which PfSUB1 is released immediately
prior to merozoite egress [14]. Recent work has shown that PKG
inhibitors in fact block the release of PfSUB1 from the exonemes
as well as blocking discharge of AMA1 from the micronemes onto
the merozoite surface; a process which is essential for merozoite
invasion of erythrocytes [15].
This first generation of PKG inhibitors showed significant
effects on progression of both the asexual blood stage (that causes
pathology) and the sexual stage (that mediates transmission) of the
malaria parasite life cycle. It has also been reported that PKG has
an essential role in the late liver stage of the rodent malaria
parasite P. berghei [16] and so this kinase has attracted interest in
terms of its potential as a drug target. An important step in the
early drug discovery pipeline is to test lead compounds for in vivo
efficacy in the rodent malaria model P. berghei. A question which
arose as part of these experiments was whether test inhibitors
would have equivalent inhibitory effects on the P. berghei and P.
falciparum PKG enzymes. It has previously been reported that
interspecies differences between the amino acid sequences of P.
falciparum falcipains and their P. berghei orthologues confer
differential inhibitor sensitivity [17,18].
To address this issue, in the present work we report
development of a GFP-expressing transgenic P. berghei line in
which the rodent malaria PKG was replaced by the P. falciparum
PKG. Although PfPKG complemented PbPKG throughout the
asexual blood stage and the early phases of sexual development,
we show that transgenic parasites exhibited markedly reduced
ookinete production that was due to a defect in the female-specific
lineage. Moreover, while the two lead compounds tested showed
no significantly different inhibitory effects of control or the Pbpfpkg
transgenic lines, the newly established line provides an in vivo
model for testing the next generation of PKG inhibitors and will
be valuable for testing inhibitors where the sensitivity of PbPKG
and PfPKG recombinant proteins differ.
Results
Generation of Pbpfpkg, a P. berghei Transgenic Line in
Which PbPKG is Replaced with PfPKG
We generated a transgenic rodent P. berghei parasite line Pbpfpkg,
in which the endogenous pbpkg gene (PBANKA_100820) was
replaced with that of the human parasite P. falciparum
(PF3D7_1436600) (Figure 1A). The P. berghei ANKA 507 clone
1 constitutively expressing GFP (WT-GFP) was used for transfec-
tion [19]. Following drug selection and cloning of the drug
resistant parasite the clones were genotyped; with integration of
the targeting vector confirmed by the presence of a 1.2 kb PCR
band for each 59 and 39 integration event in the transgenic line
using integration-specific primer pairs (Figure 1B). An additional
PCR specific for the endogenous pbpkg was performed to confirm
the absence of the endogenous gene. As expected, this PCR
resulted in the detection of a 0.7 kb band only when wild type
gDNA was used (Figure 1B). Integration was further confirmed
by Southern blotting following a diagnostic digest with BclI using a
probe corresponding to the 59UTR (Figure 1C). The blot
confirmed the absence of the diagnostic 5.1 kb band expected for
the endogenous pbpkg locus and the presence of a 3.9 kb band in
the Pbpfpkg line. Integration into the correct chromosome
(chromosome 10) was further confirmed by pulsed-field gel
electrophoresis (PFGE) (Figure 1D). Western blotting using an
anti-human PKG antibody recognising both PbPKG and PfPKG
confirmed that PfPKG is expressed in the transgenic parasites in
asexual blood and ookinete stages (Figure 1E).
Development of the Transgenic Pbpfpkg Parasite through
the Life Cycle
Blood stages and gametocytes developed normally as assessed by
Giemsa stained blood stage parasites (data not shown). Exflagel-
lation in mutant and control parasites expressing GFP in vitro
showed no significant difference between the two lines
(Figure 2A). However, ookinete conversion after 24 hours in vitro
was markedly decreased in the transgenic line (Figure 2B), with a
conversion rate of 63% in wild type and only 10% in Pbpfpkg
parasites.
When mosquitoes were allowed to feed on mice infected with
either control or mutant parasite lines, the number of oocysts
observed on day 14 post infection (p.i.) was also markedly
decreased in the Pbpfpkg line (Figure 2C). Next, we tested for the
presence of sporozoites in salivary glands on day 21 p.i., but did
not observe any sporozoites in salivary glands of mosquitoes
infected with the mutant line (data not shown). In three
independent bite back experiments 3/3 mice bitten by mosquitoes
infected with the control parasite developed a blood stage infection
on day 4–5 post bite back. Mice bitten by mosquitoes infected with
the mutant were monitored until day 14 post bite back and 0/3
mice became positive. Together these experiments show that while
PfPKG can functionally complement PbPKG in asexual blood
stages of Pbpfpkg parasites, as well as in gametocyte development
and male gametogenesis, replacement of the endogenous gene
with PfPKG leads to a decreased conversion into ookinete stages,
reduced oocyst production and no detectable sporozoites causing a
block of parasite transmission in the mosquito.
Plasmodium berghei Line Expressing the P. falciparum PKG
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Genetic Complementation Experiment with Pbpfpkg
To determine if the decrease in ookinete conversion, oocyst
production and subsequent block in sporogony is a result of a sex-
specific defect, we performed genetic crosses as described earlier to
investigate mutants with ookinete defects [20,21]. Genetic crossing
with lines that are deficient in either male (map2ko) or female
(nek4ko) gametes showed that only the male mutant map2ko line was
Figure 1. Generation of Pbpfpkg parasites. A) Schematic diagram of the endogenous pbpkg locus, the targeting construct and the transgenic
pbpfpkg locus. Areas of 59UTR and 39UTR cloned into the targeting vector are indicated, S = spacer. Arrows 1–6 indicate binding sites for primers used
in diagnostic PCR. Primers 1 and 2 were used to detect 59 integration. Primers 3 and 4 were used to determine 39 integration. Primers 5 and 6 bind
specifically to the endogenous pbpkg and are used to confirm absence of the endogenous gene in the transgenic line. The area homologous to the
probe used in Southern blotting and BclI restriction sites used for diagnostic digest are indicated. B) Diagnostic PCR used to determine integration of
the targeting construct into the Pbpfpkg transgenic line. C) Southern blot following BclI digest shows integration of the targeting construct as a
specific 3.9 kb band and absence of the endogenous 5.1 kb band in the transgenic line (Pbpfpkg) in comparison to wild type (WT-GFP). D) PFGE of wild
type (WT-GFP) and mutant parasite (Pbpfpkg) confirms integration into the correct chromosome. E) Western blot of asexual blood and ookinete stages
confirm expression of PfPKG in the transgenic line (the transgenic PfPKG bands are 25.8% and 21.8% of the PbPKG band in the WT-GFP line in asexual
blood and ookinete stages respectively).
doi:10.1371/journal.pone.0096923.g001
Figure 2. Parasite development in the mosquito. A) Exflagellation in wild type (WT-GFP) and transgenic Pbpfpkg parasites. The mean number of
exflagellation centres was 7.0 for wild type and 6.8 for Pbpfpkg parasites. Bar, mean6 SEM (Mann-Whitney U test: ns, not significant, p.0.05 compared
to WT-GFP). B) Ookinete conversion in wild type (WT-GFP) and transgenic Pbpfpkg parasites. Wild type conversion was 63% and Pbpfpkg conversion was
10%. Data shown as mean 6 SEM (Mann-Whitney U test: ***, p,0.001 compared to WT-GFP). C) Gut oocyst numbers in wild type (WT-GFP) and
transgenic Pbpfpkg parasites. Wild type infected guts contained 100 oocysts and Pbpfpkg infected guts with less than 10 oocysts. Bar, mean 6 SEM
(Mann-Whitney U test: ***, p,0.001 compared to WT-GFP).
doi:10.1371/journal.pone.0096923.g002
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able to rescue both the ookinete conversion (Figure 3A) and
oocyst numbers (Figure 3B, C) whereas the female mutant did
not show rescue of the phenotype. These experiments demonstrate
that the inability of Pbpfpkg to complete mosquito stage development
is due to a defect in the female lineage.
Effects of PKG Inhibitors on Transgenic Pbpfpkg
Development
We next tested exflagellation and ookinete conversion of both
wild type and transgenic Pbpfpkg parasites in the presence of two
ATP-competitive PKG inhibitors: compound 1 (a trisubstituted
pyrrole) and compound 2 (an imidazopyridine). PKG has
previously been shown to be the primary target of these inhibitors
during the asexual and sexual stages of the malaria parasite life
cycle [8,9,12,22,23].
Both compounds had a marked effect on exflagellation in
control and mutant Pbpfpkg transgenic parasites. Compound 2 was
more effective against both lines leading to a complete inhibition
of exflagellation at a concentration of 2 mM, whereas compound 1
led to a complete inhibition at a concentration of 5 mM
(Figure 4A).
In addition, ookinete conversion was also inhibited in control
and Pbpfpkg parasites by both compound 1 and compound 2
(Figure 4B), with compound 2 again being the more effective
inhibitor. While a concentration of 2 mM was again enough to
completely abolish ookinete conversion for compound 2, the same
effect was seen only at a concentration of 5 mM for compound 1.
The IC50 values for the inhibition of ookinete conversion by
compound 1 were 1.25 mM and 2.5 mM for control and Pbpfpkg
parasites, respectively, and 0.5 mM and 1.0 mM for compound 2.
As ookinete conversion was already markedly decreased in Pbpfpkg
parasites compared to wild type, it was not possible to determine
whether either inhibitor had a more pronounced effect on the
transgenic Pbpfpkg parasites and whether there was a differential
effect on PfPKG and PbPKG.
In vivo Effects of Compound 2 on Control and Transgenic
Pbpfpkg P. berghei Lines
We next compared the in vivo efficacy of compound 2 in control
and transgenic Pbpfpkg parasites using a standard Peters four day
test [24]. This assay was used as a proof of concept for use of the
transgenic line as a model for future in vivo efficacy testing of PKG
inhibitors. It was found that compound 2 gave an equivalent
reduction in blood stage parasitaemia of (40–50%) in both lines
(Figure 5).
Discussion
The malaria parasite protein kinase PKG has essential roles in
multiple life cycle stages both in the mammalian host and insect
vector [25]. Several recent studies have demonstrated its
regulatory functions in apical organelle release and proteolytic
processing events required for merozoite egress [13,15,22],
gametocyte activation/gamete egress [9] and in ookinete [23]
Figure 3. Genetic crossing of Pbpfpkg parasites in ookinete and oocyst stages. A) Ookinete conversion scored after crossing Pbpfpkg mutants
with either female-defective (nek4ko) or male-defective (map2ko) mutants. Wild-type parasites (WT-GFP) and map2ko mutant crossed with nek4ko
line were used as controls. Data shown as mean 6 SEM. B) For oocyst rescue, mosquitoes were fed on mice infected with WT-GFP or Pbpfpkg mutant
alone or coinfected with Pbpfpkg and either a map2ko mutant or a nek4ko mutant. Bar, arithmetic mean. C) Representative images of mosquito gut
from crosses in B). Scale bar, 100 mm.
doi:10.1371/journal.pone.0096923.g003
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and in liver stage development [16]. This suggests that this kinase
may have diverse targets/substrates during these various stages of
parasite development and they may be stage specific. These varied
functions make PKG a potentially significant antimalarial target.
Functional kinome studies have demonstrated that the pkg gene is
refractory to deletion both in P. falciparum and P. berghei [26,27].
The results generated here with the P. berghei transgenic line
expressing the P. falciparum PKG (Pbpfpkg) demonstrate that PfPKG
can complement the function of P. berghei PKG during asexual
blood stage and early sexual development; stages in which PKG is
known to be essential [9,25,26,27]. However, its function is
compromised during ookinete development and the defect even
more pronounced in terms of oocyst and sporozoite formation.
This perhaps suggests that the P. falciparum PKG is not able to
interact with one or more P. berghei-specific downstream targets
resulting in inefficient functional complementation at the latter
mosquito stages of parasite development. Among the various
possible explanations for the transgenic line being unable to
complete development in the mosquito, a sex-specific defect was a
potential candidate. A genetic complementation rescue experi-
ment demonstrated that the defect was derived from the female
lineage, suggesting a female gamete-specific P. berghei substrate that
cannot be phosphorylated by the P. falciparum PKG.
Previous functional studies using two compounds to inhibit
parasite development [9,15,25] were validated in our proof of
principle study and confirmed that this transgenic line is useful to
study the effects of P. falciparum PKG inhibitors on blood stage and
gametocyte development in an in vivo context as well as on
exflagellation. In addition, in vivo testing of PKG inhibitors on the
Pbpfpkg transgenic line showed similar levels of efficacy to those
obtained with the control line. The transgenic line will be also be a
very useful tool for in vivo screening of future generations of PKG
inhibitors where the compounds show differential inhibitory effects
using in vitro PfPKG and PbPKG kinase assays.
Materials and Methods
Ethics Statement
All animal work was approved by the United Kingdom Home
Office and passed an ethical review process. All work carried out
(under project license permit numbers 40/3344 at University of
Nottingham and 70/6996 at LSHTM) was in compliance with
European Directive 86/609/EEC for the protection of animals
used for experimental purposes and in accordance with the United
Kingdom ‘‘Animals (Scientific Procedures) Act 1986’’.
Figure 4. Inhibition of exflagellation and ookinete conversion using PKG inhibitors. A) Inhibition of exflagellation: exflagellation was
measured in the presence of increasing concentrations of compound 1 and compound 2 on both WT GFP line expressing PbPKG (WT-GFP) and the
transgenic line expressing PfPKG (Pbpfpkg) Bar, arithmetic mean 6SEM. B) Inhibition of ookinete conversion: ookinete conversion was determined in
the presence of increasing concentrations of compound 1 and compound 2 in WT-GFP and the transgenic Pbpfpkg line as above. Data shown as mean
6 SD.
doi:10.1371/journal.pone.0096923.g004
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Animals
Tuck’s Original (TO) (Harlan) outbred mice were used for all
experiments except for Peters four day tests where BALB/c
(Charles River) were used.
Generation of Replacement Targeting Construct
The replacement construct for pbpkg was constructed using the
plasmid pOB116 containing hdhfr as selectable marker for
transgenic parasites. Upstream of the selectable marker cassette
a 979 bp fragment upstream of the pbpkg ATG start codon was
amplified using the primers ApaIPKG 59-
CCCCGGGCCCCCCCAATTGACGCCATTTCAACTGAG-
39 and SacIIPKG 59-CCCCCCGCGGTTTTCTTATCTTC-
CAATCTCGTTAAC-39 and inserted using ApaI and SacII
restriction sites. The pfpkg coding region was amplified from
cDNA using the primer pair SacIIPfPKG 59-
CCCCCCGCGGATGGAAGAAGATGATAATC-
TAAAAAAAGGG-39 and BglIIPfPKG 59-CCCCAGATCTT-
TAAAAATCTATGTCCCAGTTGTCTTC-39 and inserted be-
tween SacII and BglII restriction sites. A 438 bp spacer region
corresponding to part of the pbpkg 39UTR downstream of the stop
codon was cloned between BglII and PstI restriction sites using the
primers BglIIPKG 59-CCCCAGATCTTTGAGGAAAGTGA-
TAAAAACAGAG-39and PstIPKG 59-CCCCCTGCAGCATA-
TATACATGTGTGCATTTAC-39. Downstream of the select-
able marker cassette a 1100 bp region of the 39UTR was cloned
into XhoI and NotI restriction sites using primers XhoIPKG 59-
CCCCCTCGAGTTGAGGAAAGTGATAAAAACAGAG-39
and Not1PKG59-CCCCGCGGCCGCCTGTCAGATAAA-
GAAATTTCGTTAAAAC-39.
The linear targeting sequence was released using ApaI/NotI.
For transfection, the P. berghei ANKA 507 clone 1 constitutively
expressing GFP was used as previously described [19]. The ANKA
507 clone 1 was used as a control line throughout this study.
Following electroporation parasites were mixed immediately with
150 ml reticulocyte-rich blood from a naı¨ve, phenylhydrazine-
treated mouse and incubated for 30 min at 37uC. Following
incubation, the electroporated parasites were injected intraperito-
neally (i.p.) into a naı¨ve mouse. From day 1 post infection,
transgenic parasites were selected by treating mice for four days
with 7 mg/ml pyrimethamine (Sigma) in their drinking water.
Mice were monitored for 15 days and drug selection was repeated
after passage to a second mouse. Resistant parasites obtained after
the second pressure were cloned by limiting dilution cloning and
used for genotyping.
Genotypic Analyses of Transgenic Parasites
To confirm correct integration of the targeting construct,
diagnostic PCR was set up using primers INT-PKG-5 59-
CCGTATATACTAGGATCATATATGTTC-39 and PfPKG-5-
INT-R 59-CAAAGAATTGCATATAATTAGACAGAGTC-39
for 59 integration and 539 59-CAATGATTCATAAATAGTTG-
GACTTG-39 and Int-PKG-39R 59-GTTAAAACAAATA-
TATTGGCAGGTACTAC-39 for 39-integration, both giving a
1.2 kb band in the transgenic parasites. As a control the primers
PbPKG01 59-CATATATGCTGAATATACATGTG-
TACTTTG-39 and PbPKG02 59-GTGCATAAATACGCATA-
GAAATAGAAG-39 were used, which amplify a 0.7 kb fragment
in of the wild type.
Southern blot was performed following digestion of genomic
DNA of wild type and transgenic parasites with BclI. Digested
DNA was separated on a 0.8% agarose gel before being
transferred onto a nylon membrane and being probed with a
probe homologous to the 59UTR. The probe was generated using
the Amersham AlkPhos direct labelling and detection kit (GE
Healthcare) according to manufacturer’s instructions.
Chromosomes of wild type and transgenic parasites were
separated by pulsed field gel electrophoresis (PFGE) using a
CHEF-DR III system (Bio Rad). A linear ramp of 60–500 s for
72 h at 4 V/cm was used and gels were blotted onto a nylon
membrane. A probe recognizing both the resistance cassette in the
targeting vector and the 39-UTR of the P. berghei dihydrofolate
reductase/thymidilate synthase (dhfr/ts) locus on chromosome 7 was
used to detect integration into the correct chromosome.
Western Blotting
Mixed asexual blood stages were isolated from infected blood
after removal of white blood cells using a CF11 (Whatman)
column. Blood was lysed in red blood cell lysis buffer (0.15 M
NH4Cl, 0.01 M KHCO3, 1 mM EDTA, pH 7.4). For ookinete
preparation, parasites from day 5 post infection mice were placed
in 1 ml ookinete medium for 24 hr at 20uC for ookinete
production. The parasites were then lysed in red blood cell
(RBC) buffer for 30 min and purified on a 63% NycoDenz
gradient (v/v in CLB).
Cell lysates for western blot analyses were prepared by re-
suspending parasite pellets in a 1:1 ratio of PBS containing
Protease inhibitor (Roche) and Laemmli sample buffer. Samples
were boiled for 5 min and separated on a 4–15% SDS-
polyacrylamide gel. Proteins were transferred to nitrocellulose
membranes (Amersham Biosciences) and immunoblotting per-
formed using the Western Breeze Chemiluminescent Anti-Rabbit
kit (Invitrogen) according to the manufacturer’s instructions. As
primary antibody a commercially available anti-human type-I-
PKG antibody (PK1018, Calbiochem) was used at 1:5000 [22],
which recognizes both PbPKG and PfPKG due to a C-terminal
epitope of PKG conserved between the three species. As a loading
control a rabbit polyclonal anti-GFP antibody (Invitrogen) was
used. Quantification of the band intensities was done using the
ImageJ software.
Figure 5. In vivo blood stage efficacy test using compound 2. A
Peters 4 days test was carried out using both WT-GFP and transgenic
Pbpfpkg with the PKG inhibitor compound 2. Both WT-GFP and Pbpfpkg
transgenic parasites showed a 40% reduction in blood stage
parasitaemia with compound 2 given at 25 mg/kg twice daily via the
oral route. Chloroquine (CQ) was used as control showed a 100%
reduction in blood stage parasitaemia in mice after a single daily oral
dose of 10 mg/kg.
doi:10.1371/journal.pone.0096923.g005
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Phenotypic Analyses and Parasite Maintenance
To initiate infections, blood containing 56106 parasites was
injected i.p. into mice. Parasitemia and gametocytemia were
determined on Giemsa stained blood films.
Once asexual parasitemia had reached ,7% and numbers of
gametocytes were comparable 30–50 Anopheles stephensi SD 500
mosquitoes were allowed to feed for 20 min on anaesthetised
infected mice.
Approximately 20 guts were dissected from mosquitoes on day
14 post feeding and mounted under Vaseline-rimmed cover slips
after staining with Hoechst 33342 for 10–15 min to assess mid-gut
infection. Oocysts were counted on an AxioCam ICc1 digital
camera fitted to a Zeiss AxioImager M2 microscope using a 63x
oil immersion objective.
On day 21 post-feeding another 20 mosquitoes were dissected
and their guts and salivary glands crushed separately in a loosely
fitting homogenizer to release sporozoites, which were then
quantified using a haemocytometer.
Mosquito bite back experiments were performed on day 21 post
feeding using naı¨ve mice and blood smears were examined for the
next 14 days to determine infection.
Exflagellation Assay
10 ml of parasite infected blood containing mature gametocytes
at comparable levels were placed in 50 ml ookinete medium
(RPMI1640 with 25 mM HEPES, 20% fetal bovine serum,
10 mM sodium bicarbonate, 50 mM xanthurenic acid at pH 7.6)
and incubated at 20uC. For drug testing experiments, increasing
concentrations of compound 1, 4-[2-(4-fluorphenyl)-5-(1-methyl-
piperidine-4-yl)-1H pyrrol-3-yl]pyridine, (0, 1.25, 2.5, 5 and
10 mM) or compound 2, 4-[7-[(dimethylamino)methyl]-2-(4-fluor-
phenyl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine, (0, 0.25,
0.5, 1 and 2 mM) were added to the medium. The number of
exflagellation centers per field was counted after 15 min incuba-
tion using phase contrast microscopy in 12–15 fields of view using
a 63x objective and 10x ocular lens [20].
Ookinete Conversion Assay
Parasite infected blood containing comparable levels of mature
gametocytes was re-suspended in ookinete medium as previously
described [20]. For drug testing experiments, increasing concen-
trations of compound 1; 0, 1.25, 2.5, 5 and 10 mM) or compound
2; 0, 0.25, 0.5, 1 and 2 mM) [8,9,12,22,23]) were added to the
medium prior to addition of blood. After 24 h, cells were re-
suspended in fresh ookinete medium containing an anti-P28 Cy3
conjugated 13.1 monoclonal antibody staining the surface of
activated female gametocytes and ookinetes and Hoechst
33342 DNA dye before being examined with a Zeiss AxioImager
M2 microscope. Ookinete conversion was calculated as the
percentage of ookinetes relative to all 13.1 positive cells [28].
Genetic Complementation Assay
Genetic complementation crosses were carried out between
different mutant parasite lines as described previously [20,21].
Briefly, for complementation of ookinete conversion, mature
gametocyte-containing blood from mice infected with different
parasite lines was mixed and re-suspended in ookinete medium,
and ookinete conversion was determined after 24 h as described
above. For complementation of oocyst production, mice were
infected with combinations of different parasite strains and 3–6
days old female A. stephensi mosquitoes were infected by directly
feeding on these mice. Mosquitoes were dissected 12–14 days post
infection and the presence of oocysts was determined.
In vivo Assay using Peters Four Day Test
Female mice aged 6–8 weeks (18–20 g) in groups of 5 were used
for all experiments. For each construct tested, 3 groups of 5 mice
were required (5 for Compound 2, 5 for chloroquine and 5
untreated controls). Animals were randomized and inoculated
intravenously with 26106 red blood cells parasitized with the
respective P. berghei parasite construct. Animals in the Compound
2 group were dosed twice daily for 4 consecutive days beginning
on the day of infection (i.e. D0 to D+3) at 25 mg/kg and animals
in the chloroquine group were dosed once daily at 10 mg/kg for 4
consecutive days. The parasitaemia was determined on the day
following the final treatment (D+4) and the suppression of
parasitaemia was calculated when compared to untreated controls.
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